GW Henssler & Associates Ltd. lifted its position in West Pharmaceutical Services Inc. (NYSE:WST) by 6.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,900 shares of the medical instruments supplier’s stock after purchasing an additional 184 shares during the quarter. GW Henssler & Associates Ltd.’s holdings in West Pharmaceutical Services were worth $363,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Financial Gravity Wealth Inc. purchased a new stake in shares of West Pharmaceutical Services in the first quarter valued at about $25,000. Quadrant Capital Group LLC grew its holdings in shares of West Pharmaceutical Services by 208.7% in the first quarter. Quadrant Capital Group LLC now owns 318 shares of the medical instruments supplier’s stock valued at $32,000 after purchasing an additional 215 shares during the period. Manchester Capital Management LLC purchased a new stake in shares of West Pharmaceutical Services in the first quarter valued at about $33,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of West Pharmaceutical Services in the second quarter valued at about $40,000. Finally, Machina Capital S.A.S. purchased a new stake in shares of West Pharmaceutical Services in the second quarter valued at about $42,000. 91.71% of the stock is owned by hedge funds and other institutional investors.
WST stock traded up $0.12 during mid-day trading on Thursday, hitting $146.05. 3,120 shares of the company were exchanged, compared to its average volume of 391,958. The company has a quick ratio of 2.27, a current ratio of 3.02 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $10.75 billion, a P/E ratio of 51.89, a PEG ratio of 4.15 and a beta of 1.30. The business has a fifty day simple moving average of $132.90 and a 200-day simple moving average of $117.86. West Pharmaceutical Services Inc. has a 12-month low of $91.75 and a 12-month high of $147.15.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 6th. Shareholders of record on Wednesday, October 23rd will be paid a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.41%. The ex-dividend date of this dividend is Tuesday, October 22nd. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 21.35%.
A number of brokerages recently issued reports on WST. Zacks Investment Research raised shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating and set a $158.00 price objective for the company in a report on Saturday, August 3rd. Bank of America raised shares of West Pharmaceutical Services from an “underperform” rating to a “neutral” rating in a research note on Friday, July 26th. Finally, Jefferies Financial Group lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating and set a $122.00 target price for the company. in a research note on Wednesday, May 1st. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $130.72.
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Recommended Story: What is a Market Correction?
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.